- Home
- PLRZ vs BIAF Comparison
PLRZ vs BIAF Comparison
Compare PLRZ & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLRZ
- BIAF
- Stock Information
- Founded
- PLRZ 2005
- BIAF 2014
- Country
- PLRZ Israel
- BIAF United States
- Employees
- PLRZ N/A
- BIAF N/A
- Industry
- PLRZ
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- PLRZ
- BIAF Health Care
- Exchange
- PLRZ NYSE
- BIAF Nasdaq
- Market Cap
- PLRZ 14.7M
- BIAF 12.2M
- IPO Year
- PLRZ 2024
- BIAF 2022
- Fundamental
- Price
- PLRZ $0.01
- BIAF $0.21
- Analyst Decision
- PLRZ
- BIAF Hold
- Analyst Count
- PLRZ 0
- BIAF 1
- Target Price
- PLRZ N/A
- BIAF N/A
- AVG Volume (30 Days)
- PLRZ 77.7M
- BIAF 880.8K
- Earning Date
- PLRZ 02-15-2025
- BIAF 05-15-2025
- Dividend Yield
- PLRZ N/A
- BIAF N/A
- EPS Growth
- PLRZ N/A
- BIAF N/A
- EPS
- PLRZ N/A
- BIAF N/A
- Revenue
- PLRZ N/A
- BIAF $9,362,022.00
- Revenue This Year
- PLRZ N/A
- BIAF N/A
- Revenue Next Year
- PLRZ N/A
- BIAF $19.99
- P/E Ratio
- PLRZ N/A
- BIAF N/A
- Revenue Growth
- PLRZ N/A
- BIAF 269.68
- 52 Week Low
- PLRZ $0.25
- BIAF $0.16
- 52 Week High
- PLRZ $4.80
- BIAF $2.99
- Technical
- Relative Strength Index (RSI)
- PLRZ N/A
- BIAF 32.36
- Support Level
- PLRZ N/A
- BIAF $0.19
- Resistance Level
- PLRZ N/A
- BIAF $0.24
- Average True Range (ATR)
- PLRZ 0.00
- BIAF 0.04
- MACD
- PLRZ 0.00
- BIAF -0.02
- Stochastic Oscillator
- PLRZ 0.00
- BIAF 11.72
About PLRZ POLYRIZON LTD
Polyrizon Ltd is a clinical development stage biotech company specializing in the development of nasal gels to provide preventative treatment to protect against a wide cross-section of viruses, including certain variants of COVID-19 that are also considered to cause more infections and spread faster than the original strain of the virus (the CDC expects that additional variants of the virus will continue to occur), influenza, allergens, and other toxins. Its technology platforms are Capture & Contain and Trap & Target.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.